Tenax Therapeutics, Inc. (TENX)
1.86
-0.09
(-4.62%)
USD |
NASDAQ |
Sep 11, 16:00
1.88
+0.02
(+1.08%)
After-Hours: 07:41
Tenax Therapeutics Enterprise Value : -58.55M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | -58.55M |
| September 10, 2026 | -55.67M |
| September 09, 2026 | -49.92M |
| September 08, 2026 | -54.72M |
| September 04, 2026 | -55.99M |
| September 03, 2026 | -61.11M |
| September 02, 2026 | -58.87M |
| September 01, 2026 | -60.47M |
| August 31, 2026 | -59.19M |
| August 28, 2026 | -49.92M |
| August 27, 2026 | -48.01M |
| August 26, 2026 | -50.24M |
| August 25, 2026 | -43.85M |
| August 24, 2026 | -58.87M |
| August 21, 2026 | -62.06M |
| August 20, 2026 | -61.11M |
| August 19, 2026 | -57.27M |
| August 18, 2026 | -63.66M |
| August 17, 2026 | -63.34M |
| August 14, 2026 | -60.47M |
| August 13, 2026 | -59.51M |
| August 12, 2026 | -63.02M |
| August 11, 2026 | -66.22M |
| August 10, 2026 | -74.04M |
| August 07, 2026 | 311.43M |
| Date | Value |
|---|---|
| August 06, 2026 | 307.28M |
| August 05, 2026 | 298.97M |
| August 04, 2026 | 323.57M |
| August 03, 2026 | 339.86M |
| July 31, 2026 | 319.74M |
| July 30, 2026 | 364.47M |
| July 29, 2026 | 355.52M |
| July 28, 2026 | 386.83M |
| July 27, 2026 | 399.29M |
| July 24, 2026 | 346.25M |
| July 23, 2026 | 349.77M |
| July 22, 2026 | 354.56M |
| July 21, 2026 | 384.27M |
| July 20, 2026 | 383.00M |
| July 17, 2026 | 388.43M |
| July 16, 2026 | 363.83M |
| July 15, 2026 | 372.13M |
| July 14, 2026 | 379.16M |
| July 13, 2026 | 392.58M |
| July 10, 2026 | 442.74M |
| July 09, 2026 | 467.34M |
| July 08, 2026 | 448.49M |
| July 07, 2026 | 437.31M |
| July 06, 2026 | 401.53M |
| July 02, 2026 | 375.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 7.206M |
| Century Therapeutics, Inc. | 269.22M |
| Absci Corp. | 1.211B |
| Celularity, Inc. | 109.20M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.80M |
| Total Expenses (Quarterly) | 17.80M |
| EPS Diluted (Quarterly) | -0.35 |
| Earnings Yield | -79.30% |
| Normalized Earnings Yield | -79.30 |